Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Federico II University60 enrolled

Overview

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetic Retinopathy, DR

Interventions

Faricimab Injection [Vabysmo]DRUG

One group treated with faricimab and the other one treated with Aflibercept

Aflibercept (2.0 mg)DRUG

Aflibercept 2 mg intravitreal injection

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of diabetic macular edema, diabetic retinopathy Exclusion Criteria: * previous ocular surgery, history of vitreoretinal and/or retinal vascular diseases, uveitis, myopia over 6 dioptres, significant corneal and/or lens opacity, glaucoma, ocular MNV related to other causes than nAMD, geographic atrophy, subretinal fibrosis, previous treatments for MNV

Locations (1)

University of Naples, Federico II, Napoli, Napoli

Naples, Napoli, Italy

Outcomes

Primary Outcomes

Epivascular glia regression

Time frame: From January 2025 to January 2026

Macular pigment changes

Time frame: From January 2025 to January 2026

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.